Mankind Pharma secures Rs 50 billion funding for Bharat Serums acquisition
In July, Mankind said it would acquire BSV for an enterprise value of around 136.30 billion rupees, with the majority of the deal being funded via debt
Written By : Farhat Nasim
Published On 2024-10-17 09:24 GMT | Update On 2024-10-17 09:24 GMT
Mumbai: Indian mutual funds were large buyers for a maiden bond issue from Mankind Pharma , three bankers, including one directly involved in the deal, said on Tuesday.
Mankind Pharma raised an aggregate of 50 billion rupees (USD 595.2 million) by selling bonds maturing in 18 months, two years, and in three years and one month.
The company will use the funds for the acquisition of Bharat Serums and Vaccines, the bankers said.
The bonds are rated 'AA+' by rating agencies.
In July, Mankind Pharma said it would acquire Bharat Serums and Vaccines for an enterprise value of around 136.30 billion rupees, with the majority of the deal being funded through debt.
ICICI Prudential Life Insurance, HDFC Life Insurance, SBI Life Insurance, SBI Asset Management, ICICI Asset Management, UTI Asset Management, HDFC Asset Management, Aditya Birla Sun Life Mutual Fund and Axis Asset Management were among the anchor investors, the bankers said.
Mankind Pharma and these companies did not respond to Reuters' request for comments.
"Selective high-quality corporate debentures, rated 'AA' and above, are in strong demand," said Venkatakrishnan Srinivasan, founder and managing partner at debt advisory firm Rockfort Fincap.
Mankind Pharma will pay a coupon of 7.99% each on the shorter duration papers and 7.97% on the above three-year bonds. The coupons will be payable on a semi-annual basis.
Deutsche Bank and Barclays were the arrangers for the bond issue. They did not reply to an email seeking comment.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.